Abstract
Introduction: The study is devoted to studying the expression level of the transcription factor NF-kB in the dentate gyrus of rats, which acts as one of the key mediators in the pathogenesis of neuroinflammation and neurodegeneration associated with diabetes mellitus. The aim of the study was to characterize the expression of NF-kB in the dentate gyrus of 19-month-old rats using a model of diabetes and to evaluate the modulating effect of pharmacological agents (mefargine, aminalon, and succicard). Materials and methods: in aging rats aged 12 months, type 1 diabetes mellitus (DM) was modeled for 6 months by a single injection of streptozotocin (Sigma, USA) dissolved in citrate buffer (0.1 M, pH 4.5) at a dose of 60 mg/kg after 48 hours of food deprivation intraperitoneally. After reaching the age of 18 months, the animals were injected with GABA derivatives for 4 weeks: mefargine, aminalon and succicard. NF-kB was detected by immunohistochemical examination using primary antibodies to the NF-kB protein on paraffin frontal sections of the rat brain. Results: An immunohistochemical study revealed an increase in the expression of NF-kB, an immunoreactive material in the cytoplasm of pericaryons of neurons and the neuropile of the granular and subgranular layers in the dentate gyrus in rats with DM compared with intact animals, reflecting a profound violation of cellular homeostasis and activation of neuroinflammation in brain structures. Cells with a moderate expression level appeared in the cytoplasm of the pericaryons of the neurons of the granular layer, as well as in the neuropile of the granular layer and in the nerve cells of the subgranular layer. Whereas in the intact group, only a few cells had a weak expression level. In animals with DM, which were injected with the studied compounds (aminalon, mefargine, succicard), the expression of NF-kB-immunoreactive material decreased compared with the DM group without treatment. The restorative effect of the studied drugs confirms the expediency of their use for the correction of metabolic disorders in the brain in diabetes mellitus and aging.

This publication has 13 references indexed in Scilit: